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Functional Expression and Analysis of a Human
Nickel-induced contact dermatitis represents a T cell mediated delayed type hyperreactivity. The elucidation of the molecular basis of T cell activation by Ni 2⍣ ions may serve as a model for the understanding of other metal allergies. We describe here the expression of hybrid T cell antigen receptor (TCR) α-and β-genes, containing rearranged human Ni-reactive variable and mouse constant regions, together with human CD4 in a mouse T cell hybridoma. The resulting hybridoma specifically responds to IL-2 secretion to Ni, but not to other metal ions in the presence of HLA-matched antigenpresenting cells. Loss of CD4 decreases, but does not completely abrogate this reactivity. The restricting HLA-DQ element is identified as consisting T he αβ type of the T cell antigen receptor (TCR) is typically activated by major histocompatibility complex (MHC)-associated peptides on the surface of antigen-presenting cells (APC) (Jorgensen et al, 1992; Germain, 1994) . The recent literature, however, also reveals examples for αβ as well as γδ TCR that interact with non-peptide molecules such as carbohydrates, pyrophosphates, or lipoglycans (Corinti et al, 1997; Harding et al, 1993; Haurum et al, 1994; Morita et al, 1995; Sieling et al, 1995; Tanaka et al, 1995) . Haptens in the form of drugs or chemicals in cosmetics or the environment represent major sources of allergens or contact sensitizers (Dupuis and Benezra, 1982) . Such contact sensitivities to haptens are initiated and determined in their specificity by hapten-specific T cells (Kapsenberg et al, 1992) . The most common form of contact dermatitis in the caucasian population is induced by metal ions from nickel-containing alloys (e.g., in jewellery and clips) and is known as nickel allergy (Basketter et al, 1993; Schaller et al, 1994) . T cells from the peripheral blood or skin lesions of Ni-allergic patients have been shown to proliferate in response to Manuscript received August 10, 1998; revised March 8, 1999 ; accepted for publication March 30, 1999 Reprint requests to Dr H.U. NiSO 4 and to require HLA-matched APC (Sinigaglia et al, 1985; Kapsenberg et al, 1987; Emtestam et al, 1989; Moulon et al, 1995) . It has therefore been argued that Ni 2ϩ ions, which form squareplanar coordination complexes with amino acids of certain proteins or peptides (Martin, 1988) , may function like covalently reactive haptens to form antigenic epitopes for T cells (Romagnoli et al, 1991; Basketter et al, 1995) . Indeed, mouse model-haptens, such as di-or trinitrophenyl reagents, urushiol, p-azobenzene-arsonate, and others, have been shown to form covalent conjugates with MHC-associated peptides as epitopes for T cells (Nalefski and Rao, 1993; Romero et al, 1993; Weltzien et al, 1996; Gelber et al, 1997) . Also in the case of human penicillin allergy, HLA-binding penicilloyl peptides have been identified as T cell antigenic determinants (Padovan et al, 1997) . In contrast, the structural identity of the antigenic epitopes that activate Ni-reactive T cells remains obscure. So far, it is unclear whether the metal ions are actually part of the antigenic determinants or only indirectly involved in their production (Sinigaglia, 1994; Lepoittevin and Leblond, 1997) . It also remains to be investigated how strictly the phenomenon of MHC restriction applies to metal reactive T cells and whether the TCR is the only structure to mediate Ni-reactivity.
In murine systems, hapten-reactive T cell hybridomas have greatly contributed to the elucidation of relevant T cell epitopes as well as of their molecular interactions with the respective TCR (Nalefski et al, 1990; von Bonin et al, 1993) . Because human T cells do not form stable T cell hybridomas, this study deals with the functional co-expression of TCR α-and β-chain genes isolated from human, Ni-reactive T cell clones together with human CD4 in a receptor-deficient mouse T cell hybridoma line.
MATERIALS AND METHODS

T cell stimulants and growth factors
The following reagents were applied at the indicated concentrations, if not specified otherwise: NiSO 4 ϫ6H 2 O, 10 -4 M; CoCl 2 ϫ6H 2 O, 5ϫ10 -5 M; ZnSO 4 ϫ7H 2 O, 7.5ϫ10 -6 M; CuSO 4 ϫ5H 2 O, 10 -5 M; PdCl 2 , 5ϫ10 -4 M (all obtained from Sigma, Deisenhofen, Germany); phytohemagglutin (PHA-P) (Murex, Dartford, U.K.), 1µg per ml; bacterial superantigen SEC2 (staphylococcal enterotoxin C2) (Serva, Heidelberg, Germany), 0.1µg per ml. Rat ConA supernatant, a 24 h supernatant of ConA-stimulated rat spleen cells, served as a source of IL-2 to maintain CTLL cells (Grabstein et al, 1986) .
Antibodies and flow cytometry
The following hamster monoclonal antibodies (MoAb) were used for flow cytometry: anti-murine CD3ε (145-2C11) (Leo et al, 1987) and anti-murine TCRαβ (H57-597) (Kubo et al, 1989) . Mouse anti-human MoAb used included: FITC-conjugated and non-conjugated TCRBV13S6 (JU74.39), FITC-conjugated CD4 (13B8.2), HLA-DQ (SLVP3), FITC-conjugated ICAM-1 (84H10), FITCconjugated CD80 (MAB104), FITC-conjugated ICAM-2 (B-T1), FITCconjugated CD58 (AICD58), FITC-conjugated CD11a (25.3.1), PEconjugated CD40 (MoAb89), and PE-conjugated ICAM-3 (HP2/19) (all from Immunotech, Marseilles, France), FITC-conjugated HLA-DR (B8.12.2) (Becton-Dickinson, San Jose, NM), and Biotin-conjugated CD86 (IT2.2) (Pharmingen, San Diego, NM). Secondary antibodies used were: FITC-conjugated goat anti-mouse Ig and goat anti-hamster Ig (Dianova, Hamburg, Germany). Streptavidin-RED670TM (Gibco/BRL, Eggenstein, Germany) and FITC-conjugated mouse IgG1 (MOPC-21) (Sigma) were also used. For flow cytometric analysis, 2 ϫ 10 5 cells were stained at 4°C in 96 well round bottom plates either directly with a fluorescence-labelled MoAb or with an unlabelled MoAb, followed by staining with the appropriate secondary MoAb. Fluorescence was determined in a FACScan instrument (Becton-Dickinson). For sorting of hybridomas, transfectant 54PPN8 was stained with CD4 MoAb and co-receptor loss variants were sorted with a FACS sorter (Becton-Dickinson).
Cells and growth media
The Ni-specific human CD4-positive T cell clone PPN82 was isolated from the Ni-allergic donor PPN (Pistoor et al, 1995) and was cultured as described previously (Moulon et al, 1995) . The murine T cell hybridoma 54ζ17 was a gift of O. Acuto (Institut Pasteur, Paris, France), and has been described previously (Blank et al, 1993) . This hybridoma is a variant of the TCR-negative T cell hybridoma 58α -β - (Letourneur and Malissen, 1989) , transfected with vectors for the human CD4 molecule (conferring resistance to mycophenolic acid) and the murine CD3ζ chain. All T cell hybridomas were maintained in RPMI 1640 supplemented with 2 mM L-glutamine, 100 µg kanamycin per ml (all from Gibco/BRL), 5 ϫ 10 -5 M 2-mercaptoethanol (Roth, Karlsruhe, Germany), and 10% heat-inactivated fetal calf serum (RPMI-FCS). The following EBV-transformed B cell lines were used as APC and known HLA-DR and -DQ haplotypes are given in parentheses: BG (DRB1*0101, DRB1*14); JESTHOM (DRB1*0101, DQA1*0101, DQB1*0501); EHM (DRB1*0101, DQA1*0101, DQB1*0501); LWAGS (DRB1*0102, DQA1*0101, DQB1*0501). In one set of experiments, additional nickelspecific T cells [the human T cell clone 3 and the T cell transfectant T913 (TCR of clone 9)] were used as responder cells. Both were derived from the donor SE. After 20 h at 37°C, 100 µl of the supernatant were used for a CTLL assay as described previously (Grabstein et al, 1986) . In some experiments, APC were fixed as described by Shimonkevitz et al (1983) .
Briefly, B cells were suspended in 1 ml phosphate-buffered saline containing 0.05% glutaraldehyde (Gibco/BRL) for 45 s at room temperature. The reaction was stopped by adding 1 ml of 0.2 M L-lysine (Gibco/BRL) for an additional 45 s. Cells were then washed and in some experiments pulsed for 90 min at 37°C with 10 -4 M NiSO 4 and washed before being used as APC as described above. For T cell restriction specificity, T cells were cultured with B cells, metal-salt, and either anti-DR (L243, ATCC), anti-DP (B7.21, ATCC), or anti-DQ (SVPL3, ATCC) MoAb as 1:10 culture SN. IL-2 secretion was determined as above.
PCR methodology and TCR expression vectors
Oligonucleotide primers employed in this study were as follows: Leader Vα18, ACTCC-AGTGGCTCAGAAAATGGAGAAGAATCCTTTG; Jα-Splice-BamHI, GATCGGATCCacttacCTGGATTCACGGTTAAGG; mutα18/s, TTC-AGGCTGGGAACCTTTGAT; mutα18/as, ATCAAAGGTTCCCAGC-CTGAA; Pr-Vα4 CAATGTTTTTCACAGCTGTGCATCA; Pr-Vα18, CATTTTCTGAGCCACTGGAGTGTGTG; Leader Vβ13, ACCTGC-CTTGGTCCCAAGATGAGCATCAGCCTCCTG; Jβ-Splice-SalI-82, GATCGTCGACtcttacCTGTCACAGTGAGCCTGGTCCCG; Pr-Vβ8-EcoRI, GATCGAATTCTTTGTGTAAGGAAGGGTGTGGT; Pr-Vβ13, CATCTTGGGACCAAGGCAGGTTCTTG; P5ЈDQA1, ATGG-TGTAAACTTGTACCAGT; P3ЈDQA1, TTGGTAGCAGCGGTAGA-GTTG; P5ЈRevM13DQB1, CAGGAAACAGCTATGACCCATGTG-CTACTTCACCAACGG; P3ЈDQB95011b, CAGGATCCCGCGGTA-CGCCA. Restriction sites for BamHI, SalI, and EcoRI are in bold print. The primer pair mutα18/s and mutα18/as was used to eliminate an endogenous BamHI site in the TCRAV18S2 element prior to the final cloning steps without altering the amino acid sequence (mutated nucleotides are underlined). Splice sites (indicated by lower-case letters) were introduced into the two primers Jα-Splice-BamHI and Jβ-Splice-SalI-82 to allow for correct splicing of the genomically arranged exons of the TCRA and TCRB constant regions. Standard PCR procedures included 36 cycles of 1.2 min at 95°C, 2 min at 55°C, and 2 min at 72°C in 100 µl volumes using 200 µM dNTP (Pharmacia, Freiburg, Germany), 10 µM of each primer, 1ϫPfu buffer (Stratagene, Heidelberg, Germany), and 2.5U Pfu polymerase (Stratagene). Total RNA was extracted from 5 ϫ 10 6 cells of clone PPN82, transcribed into cDNA, and screened by PCR for rearranged VA-and VB-elements as previously described to determine the TCRJelements and to ensure functionality of the rearrangements (Vollmer et al, 1997) . The primer pairs P5ЈDQA1P3ЈDQA1 and P5ЈRevM13DQB1/ P3ЈDQB95011b were used for specific amplification of the second exon of the DQA1 gene and of the DQB1*05 allele after DNA extraction (NatuTec, Frankfurt, Germany). PCR procedures for DQ amplification included 1 cycle of 2 min at 98°C, 5 cycles of 1 min at 95°C, 2 min at 60°C, and 1 min at 72°C followed by 32 cycles of 1 min at 95°C, 30 s at 55°C, and 1 min at 72°C. PCR was performed in 13 µl volumes using 20 µM dNTP, 1 µM of each primer, 2 mM MgCl 2 (Eurogentec, Seraing, Belgium), 1ϫTaq buffer (Eurogentec), and 0.5U Taq polymerase (Eurogentec). PCR reaction products were purified and sequenced. Sequencing was performed using the Big Dye terminator cycle sequencing ready action kit (Applied Biosystems, Warrington, U.K.) on the ABI automatic sequencer (Applied Biosystems). To replace the variable mouse TCR regions in the expression vectors pV2-15α and pV2-15β (Casorati et al, 1993) , the mouse TCR sequences were excised by either SacI and BamHI (pV2-15α) or EcoRI and SalI for pV2-15β (all enzymes from Gibco/BRL) (Fig 1a) . Human variable regions, including the partially removed mouse promoter sequences, were constructed in a series of PCR reactions with overlapping intermediates (Table I and Fig 1b) . In the case of the α-chain, it included the mutational destruction of an internal BamHI restriction site by the primer pair mutα18. PCR product 3 was cloned into pTZ19 (Amersham) and sequenced (Vollmer et al, 1997) to ensure mutation of the BamHI restriction site. The final PCR products 5 and 8 were cloned into pTZ19, sequenced, excised with SaI/BamHI or EcoRI/ SalI, respectively, and recloned into the digested vectors pV2-15α or pV2-15β. The resulting mouse/human hybrid expression vectors were designated pV2-82α18 and pV2-82β13 (Fig 1b) . These vectors were linearized for transfection with ClaI (α-vector) or EcoRI (β-vector).
Transfection of the mouse T cell hybridoma 54ζ17 Eight ϫ 10 6 54ζ17 recipient cells were transfected with 1 µg pV2-82α18 and 4 µg pV2-82β13 in a Gene Pulse Cuvette (BIORAD, Hercules) by electroporation. After 48 h, the cells were selected in 1.5 mg G418 per ml (Gibco/ BRL). Resistant cultures were analysed by FACS for surface expression of TCR/CD3.
RESULTS
Functional expression of a human Ni-specific TCR in a mouse T cell hybridoma The human CD4 ϩ T cell clone Leader Vα18 Jα-Splice-BamHI PCR 1 ϩ 2 4 P r -V α 4 P r -V α 18 pV2-15α 5 P r -V α 4 J α -Splice-BamHI PCR 3 ϩ 4 TCRB chain 6 Leader Vβ13 Jβ-Splice-Sal I-82 PPN82, cDNA 7 P r -V β 8-EcoRI Pr-Vβ13 pV2-15β 8 P r -V β 8-EcoRI Jβ-Splice-Sal I-82 PCR 6 ϩ 7 a For primer sequences see Materials and Methods. Approximate locations of primer sequences in the constructs are indicated by arrows in Fig 1(b) .
PPN82 (isolated from the peripheral blood of the Ni-allergic donor PPN) was screened by PCR for TCRA and TCRB use. One inframe TCRB-chain (VB13S6A2T, DB1, JB1S6, CB1) and two TCRA-chains were identified, one of the latter (VAD14S1, JA44) was rearranged out of frame. The functional TCRA sequence contained a new member of the VA18 family (VA18S2) rearranged to JA53 (Fig 1a) . The surface expression of VB13 was confirmed by FACS analysis (Fig 2b) .
The rearranged V(D)J-regions of the functional TCRA-and TCRB-chains were amplified by PCR and cloned into previously described expression vectors (Casorati et al, 1993; von Bonin et al, 1996) as described in the Materials and Methods and Table I . The resulting vectors pV2-82α18 and pV2-82β13 (Fig 1b) contained human variable sequences together with mouse constant and regulatory TCR sequences. They were transfected into the TCRnegative murine T cell hybridoma 54ζ17, which also expressed the human CD4 co-receptor (Blank et al, 1993) , but no endogenous murine CD4 molecule (Glaichenhaus et al, 1991) . This recipient cell line also lacks expression of endogenous TCRA and TCRB chains as shown in Fig 2(a) . A panel of transfectant lines was analysed for surface expression of TCR and co-receptor using MoAb against VB13S6 and human CD4. T cell hybridoma 54PPN8 was chosen as a representative hybridoma for further experiments as it homogeneously expressed the chimeric TCR as well as the human CD4 co-receptor. FACS data are shown in Fig 2(a) in comparison with the TCR donor clone PPN82 (Fig 2b) .
Functionality of the expressed TCR was assessed by stimulation with MoAb specific for either mouse CD3ε or human VB13S6 or with staphylococcal superantigen SEC2 in the presence of the irradiated B cell line BG. As shown in Fig 2(c) , the transfectant 54PPN8, but not the untransfected hybridoma 54ζ17, responded to each of the three stimuli.
Nickel-specificity and HLA-DQ restriction of the TCR transfectant
The transfectant 54PPN8 as well as the TCR donor clone PPN82 were co-cultivated with the irradiated B cell line BG and graded concentrations of NiSO 4 (Fig 3a) . IL-2 secretion by the transfectant followed the same dose dependence of NiSO 4 as the proliferative response of the original clone. In contrast, the TCR-recipient cell line 54ζ17 was not stimulated by NiSO 4 in the presence of the irradiated B cell line BG (Fig 3a) . In Fig 3(b) as well as in Fig 3(c) , the B cell line JESTHOM was used as APC because the donor PPN was HLA-typed as DQA1*0101, DQB1*0501, and DQB1*0201/0202, and this B cell line is homozygous for the HLA-genes DQA1*0101 and DQB1*0501. Figure 3(b) reveals that the Ni-specific response requires the simultaneous presence of both APC and NiSO 4 . As for the original clone PPN82, no activation of the transfectant with Zn, Pd, Co, or Cu was observed, and activation by Ni was abolished when NiSO 4 -pulsed APC were washed prior to stimulation of the TCR transfectant (data not shown). Figure 3(b) also illustrates that glutaraldehyde fixation reduced but never completely abolished the antigen-presenting capacities of the APC. Fixation of B cells JESTHOM was done under conditions previously shown to completely abolish the stimulatory capacity of APC for some Nireactive T cell clones (Moulon et al, 1995) . Thus, PPN82 and the resulting transfectant 54PPN8 belong to the class of Ni-reactive T cells we described earlier (Moulon et al, 1995) , which do not require antigen processing for Ni-recognition.
Concerning the specificity of HLA-restriction, it first appeared that only HLA-DR1 expressing APC mediated the reaction (not shown); however, as shown in Fig 3(c) , the Ni-reactivity was effectively inhibited by MoAb to HLA-DQ, but not to HLA-DR or HLA-DP. Furthermore, 54PPN8 was stimulated in the presence of APC homozygous for DQA1*0101 and DQB1*0501 (Fig 3b) . The anti-DQ antibody was also effective in blocking the Nireactivity of clone PPN82 (not shown). Consequently, B cells negative for DQB1*0501 failed to stimulate 54PPN8 (not shown).
Influence of different HLA-DQ5 positive B cell lines on Nirecognition
We further compared the Ni-presenting potential of the APC line BG with several reference EBV-transformed B cell lines, i.e., EHM, LWAGS, and JESTHOM, all of which are homozygous for the HLA class II genes DQA1*0101 and DQB1*0501. All of these APC supported SEC2-mediated activation of 54PPN8 as demonstrated in Fig 4(a) . The HLA-DQ molecules expressed on the cell lines JESTHOM and BG were perfectly able to present Ni to the transfectant and the reaction was inhibited by anti-DQ MoAb; however, the other two B cell lines (EHM and LWAGS) were extremely poor stimulators in spite of expressing the same HLA-DQA/B combination. This result was not due to variations in HLA-DQ expression as the mean fluorescence intensity of anti-HLA-DQ staining (numbers in parentheses in Fig 4a) indicated a very similar surface density of HLA-DQ on all four APC. We also did not find any significant differences in the expression of the adhesion molecules or costimulatory molecules ICAM-1, ICAM-2, ICAM-3, LFA-1, LFA-3, B7-1, B7-2, and CD40 (not shown), which are, among others, important for interaction of T cells with APC. Functional integrity of all four APC lines was indicated by their ability to mediate SEC2 activation of 54PPN8. In addition, because three of the four APC (except for LWAGS) also expressed the DRB1*0101 allele, they were tested as Ni-presenters for the TCR transfectant T913, which reacts to Ni presented on DRB1*0101-expressing APC (Moulon and Vollmer, unpublished data) . As shown in Fig 4(b) , all three DRB1*0101-expressing APC including EHM induced a Nispecific release of IL-2 from this transfectant. We also tested the stimulatory capacity of the APC lines BG, JESTHOM, and EHM on a Ni-specific, DQ-restricted human T cell clone (clone 3, Fig  4c) . In contrast to the hybridoma 54PPN8, clone 3 was strongly activated in the presence of Ni by EHM, but only marginally by JESTHOM. Thus, our data reveal opposing stimulatory capacities of the DQ5-positive B cell lines JESTHOM and EHM for different T cells, including a TCR transfected hybridoma as well as a genuine T cell clone.
To investigate whether variations in the individual HLA-DQ5 sequences were responsible for the observed differences in Nipresentation, we sequenced exon 2, coding for the polymorphic regions of HLA-DQA1*0101 and DQB1*0501, of the APC lines EHM and JESTHOM. Both sequences revealed complete identity to the previously published HLA-DQA1*0101 and DQB1*0501 sequences (available under accession numbers L34082 and X03068, respectively) (data not shown).
Influence of the CD4 co-receptor on Ni-recognition It is well established that CD4 and CD8 co-receptor molecules play an important part in TCR-mediated T cell activation (Glaichenhaus et al, 1991; Garcia et al, 1996; König et al, 1996) ; however, it is also known that the influence of the co-receptors may vary significantly (Janeway, 1992) and that in some cases co-receptor is even not required for antigen recognition (Shi et al, 1998) . We therefore have isolated several CD4-negative variants of 54PPN8 by FACS-sorting and cloning. Figure 5 compares FACS profiles of three CD4
-transfectant clones (Figs 5a-c) and one CD4 ϩ transfectant clone (Fig 5d ) . These clones all showed TCR expression similar to the original TCR transfectant 54PPN8 as analysed in Fig 2(a) , whereas for the CD4-negative clones, no co-receptor expression was detectable. All five cell types revealed indistinguishable IL-2 responses to stimulation with anti-TCRB13S6 MoAb (Fig 5e) ; however, the magnitude of the response to NiSO 4 was clearly reduced for the CD4 loss variants (Fig 5f ) .
DISCUSSION
Contact hypersensitivity to nickel represents the most common of numerous metal-induced human allergic disorders and may serve as a model to elucidate the cellular and molecular basis for these types of allergies. It is well established that Ni-reactive T cells represent the specificity-determining elements in Ni-allergy (Kapsenberg et al, 1992) ; however, studies aiming at identifying the antigenic epitopes involved in Ni-specific T cell activation have so far been unsuccessful (Sinigaglia, 1994; Griem et al, 1998) .
In mouse systems, the production of class I and class II MHCrestricted T cell hybridomas has spurred the identification of peptide as well as of hapten epitopes (Nalefski et al, 1990; von Bonin et al, 1993) . Human T cells, in contrast, cannot be fused to produce stable hybridomas, and the only way to immortalize them is either by virus transformation (Meinl et al, 1995) or by transfection of human TCR genes into Jurkat cells or receptor-less variants of mouse T cell hybridomas (Ohashi et al, 1985; Bukowski et al, 1995; Fleischer et al, 1996) . We have adopted the latter technology and combined it with a method originally developed to express mouse TCR (Casorati et al, 1993; von Bonin et al, 1996) . This approach also circumvents the problem of self-presentation of antigen in the absence of APC because mouse hybridomas, unlike activated human T cells, do not express human HLA class I or class II molecules.
In this study, therefore, we constructed hybrid human/mouse expression vectors for the TCR α-and β-chain of a human Nispecific T cell clone. Similar to other published human/mouse TCR hybrids (Blank et al, 1993) , these constructs contained the complete constant regions of the mouse TCR joined to the rearranged human variable regions. The induction of IL-2 secretion in the resulting TCR transfectant 54PPN8 by antibody-, by superantigen-, and especially by antigen-stimulation proves that these chimeric molecules are capable of signal transmission from the plasma membrane to the nucleus in response to antigen. The identical antigen-specificity and -sensitivity of the transfectant and the T cell clone (Fig 3) identifies the TCR of a Ni-reactive T cell clone as the only structure required to define its Ni-specificity. Moreover, the quantitative dependence of Ni-specific responses on the presence of CD4 co-receptors strengthens the point that the MHC-restricted interaction of TCR with Ni-determinants more closely resembles interactions of TCR with nominal peptide antigens (Hampl et al, 1997) than CD4-independent interactions with certain peptides (Hastings et al, 1996; Shi et al, 1998) or with superantigens and mitogens. The failure to completely abolish Nireactivity by glutaraldehyde fixation of the APC places clone PPN82, as well as the transfectant 54PPN8, among those Ni-reactive T cells (Moulon et al, 1995) , which apparently do not require entry of Ni into the cell to form relevant determinants. Ni 2ϩ ions, therefore, may be envisaged as forming structural parts of the antigenic determinants for such clones. It is still unclear, however, whether the epitope depends on the nature of the peptides embedded within the binding groove of the restricting HLA molecule or whether the metal ions form peptide-independent complexes between TCR and HLA (Sinigaglia, 1994) .
In this respect, the data of Fig 4 are of particular relevance. There we demonstrated that the restricting DQ5 element consisting of DQA1*0101 and DQB1*0501, when expressed on different human B cell lines homozygous for these HLA-DQ genes, exhibited dramatic variations in its capability to present Ni to 54PPN8. Some of the B cell lines (EHM and LWAGS) were poor stimulators for this transfectant, although all APC were comparable in superantigenmediated activation of 54PPN8. These differences were not due to a general inability of some of the APC to present antigen, as the B cell Line EHM effectively presented Ni to another Nireactive TCR transfectant in a DRB1*0101-restricted manner. Moreover, the variable Ni-presenting capacity of identical HLA-DQ5 molecules on different B cell lines was not restricted to mouse T cell hybridomas but was also observed for a human T cell clone. The nickel-specific T cell clone 3 and the hybridoma 54PPN8 (both DQ5-restricted) showed opposing responses to the two B cell lines JESTHOM and EHM in antigen-mediated TCR activation (Fig 4a versus 4c) . This latter finding in addition to rather small differences in the surface expression of HLA-DQ and a variety of adhesion and costimulatory molecules, suggests qualitative differences between sequence-identical DQ5-molecules on different cells. A similar phenomenon has been reported by Emtestam and Olerup (1996) for a DR4-restricted, Ni-reactive, human T cell clone. Our data support their hypothesis that variations of the endogenous peptide pool in the MHC binding groove might be responsible for the observed effects. It remains to be seen whether this indicates a hapten-like interaction of Ni 2ϩ ions with specific MHC-bound peptides (Romagnoli et al, 1991) or a particular, peptide-induced MHC-conformation. Factors independent of the nature of the HLA-associated peptides may also be involved, however. It should also be considered that the phenomenon described here may represent one of several different mechanisms for the activation of T cells by Ni 2ϩ ions. In fact, the complexity of T cell activation by Ni salts may reflect the situation that individual TCR substantially differ in their molecular mode of interaction with Ni-treated APC.
The approach we applied in this study resulted in immortalization of human Ni-specific TCR. This simplified culture conditions and allowed the investigation of the role of TCR and TCR coreceptors in Ni-recognition. In addition, this method provides us with a new tool, which will now greatly facilitate studies aiming at the elucidation of Ni-induced T cell epitopes and their molecular interactions with TCR by mutational analysis. 
